Huangpu biomedicine, healthcare industries show robust growth

The combined operating revenue among all biomedicine and healthcare enterprises above designated size in Guangzhou's Huangpu district reached 58.3 billion yuan ($8 billion) in the first half of this year, up 5.5 percent year-on-year.

Da An Gene Co Ltd recorded an operating revenue of 2.1 billion yuan, a year-on-year increase of more than 300 percent, while Guangzhou Wondfo Biotech Co Ltd recorded an operating revenue of over 1.6 billion yuan, up more than 200 percent year-on-year.

The total output value of the pharmaceutical production and medical equipment manufacturing industries exceeded 11 billion yuan, a year-on-year increase of 45 percent.

After the COVID-19 outbreak, Huangpu released a series of supportive measures and an accumulative fund of more than 70 million yuan, which has helped more than 200 local biomedicine enterprises weather operational difficulties.

In addition, local enterprises are being encouraged to develop and produce anti-epidemic products such as vaccines, drugs, and test gadgets, which have been sold to 61 countries and regions. The yield of COVID-19 diagnostic kits in Huangpu accounts for a quarter of the nation's total.

Share - WeChat